UPCC 07917: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
Enrolling By Invitation
99 years or below
All
25 participants needed
1 Location
Brief description of study
TBD
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: solid tumor, cancer
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 828778
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
